Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.
We describe a clinical syndrome occurring after contrast medium injection in patients who previously received recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha 2A treatment for metastatic renal cancer. The clinical picture mimics many aspects of rIL-2-related systemic side effects. The patients were managed conservatively but the potential for severe manifestations can occur, requiring more intensive treatment.
Abi-Aad
A S
AS
Department of Surgery, UCLA School of Medicine.
Figlin
R A
RA
Belldegrun
A
A
deKernion
J B
JB
D002292:Carcinoma, Renal Cell / Q000628:therapy*; D003287:Contrast Media / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D003287:Contrast Media; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins